Nangona ekuqalekeni iCervarix ingabonakali iyinto efanelekileyo yokukhusela ukusuleleka kwi- HPV njenge- Gardasil okanye i- Gardasil 9 , ngokwenene yinto ekhethekileyo yokugonya. Nangona idibeneyo eyenzelwe ukukhusela kuphela iimiba ezimbini zomngcipheko we-HPV (16 no-18) odla ngokuqhagamshelana nomhlaza womlomo wesibeleko (ubuncinci kwi-Women's Caucasian ), xa kuthelekiswa nezinye izitofu ezijoliswe kwiintlobo ezine-9 okanye ezili-9, eziliqela Izifundo zinike ubungqina obubonisa ukuba iCervarix ngokwenene inakho ukukhusela uluhlu olubanzi lweengxaki ze-HPV ze- oncogenic , eziquka, mhlawumbi, i-HPV 31, 33, 35, 45, 52, no-58.
Nangona kunjalo, ngokungafani ne-Garadsil, akunakwenzeka ukukhusela naluphi na uhlobo lweengcipheko ezisezantsi ezithinteka kwiimfazwe zesini .
I-Cervarix ayikho yodwa ekunikeni amandla okubonelela ukukhuselwa kweminye i-HPV. I-Gardasil nayo ibonakala inakho amandla okubonelela ngokukhusela ukukhusela kwiintlobo ezahlukeneyo ze-HPV, kodwa ubungqina obuya kumhla, nangona zingavumelaniyo, bubonisa ukuba ubukhulu bokukhusela ukhuseleko alukwazi ukuba lukhulu kangangoko ku-Cervarix. Ukongezelela, abanye abaphandi baqhathanisa nokukwazi ukukhusela iindidi ze-HPV ukufumana ukukhusela ukukhuselwa kwiintlobo ezahlukeneyo ze-HPV baye bafumana ubungqina bokuba ukukhuselwa yiCervarix kunokuhlala ixesha elide kunokukhuselwa yi-Gardasil.
Ngamafutshane, isixa-mali sobungqina sibonisa ukuba inketho yokugonya ye-HPV yinto enhle ... kwaye ukuba izitofu ezimbini zihlawulwa ngendlela efanayo. Inzuzo enkulu ye-Gardasil kukukwazi ukukhusela kwiimfazwe zesini kunye neentlobo ezahlukeneyo zomhlaza .
Inzuzo ephambili yeCervarix kukuba inokunika ukhuselo olunamandla kunye nexesha elide kunye neentlobo ezahlukeneyo zomhlaza.
Hayi, kwaye kukho enye inzuzo engaba yiCervarix ngaphezu kweG Gardasil, ubuncinci kubemi abemi babemi. Ekupheleni konyaka ka-2013, iKhomishoni yaseYurophu yavunywa ishedyuli yokunciphisa i-injection schedule of two injections, endaweni yesithathu, kumantombazana aneminyaka engama-9 ukuya kwe-14.
Ishedyuli ye-2-dose ayisakwamkelwa e-United States, kodwa ukuba kwaye nini, ingaba ngumgqugquzeli onamandla kwabanye abantu ukuba bakhethe ugonyo kunye neCervarix ngaphezu kokugonya kunye ne-Gardasil. Ukuba ungumntu othiya iigciwane, okanye ukuba unemali okanye ezinye izinto ezixhalabisa malunga nokugonywa, ukugqitywa emva kokukhangela amabini kunokuba kunomtsalane ngakumbi kunokuba ufuna ukubuyela ngenombolo yesithathu.
Imithombo:
I-Bissett SL, i-Draper E, i-Myers RE, i-Godi A, iibhedi I-anti-neutralizing antibodies ezifunyenwe yi-Cervarix® yomntu wokugoma i-papillomavirus ibonisa uluhlu lwe-Alpha-9 e-type-type. Igciwane. 2014 Feb 26; 32 (10): 1139-46. i-doi: 10.1016 / j.vaccine.2014.01.008.
Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, MP MP, David L, Struyf F, Dubin G. Ukuthelekiswa kwexesha elide kunye nokukhuselwa kompapillomavirus wabantu (HPV) -16 / I-AS04-vaccinate vaccine kunye ne-HPV-6/11/16/18 yokugonywa kwabasetyhini abanempilo abaneminyaka eli-18 ukuya ku-45 ubudala: Ukuhlaziywa kokugqibela kokuhlolwa kweSigaba III sovavanyo olulinganisiweyo. Hum Vaccin Immunother. 2014; 10 (12): 3435-45. i-doi: 10.4161 / hv.36121.
U-Kohli M, u-Lawrence D, u-Haig J, u-Anonychuk A, u-Demarteau N. Ukumodela umphumo wokohluko phakathi kwedatha yokukhusela i-papillomavirus (HPV) -16/18 yokugonywa kwe-AS04 kunye ne-papillomavirus yabantu (HPV) -6 / Igciwane le-11/16/18 eCanada. BMC yezeMpilo. Ngo-2012 Oktobha 13; 12: 872. i-doi: 10.1186 / 1471-2458-12-872.
UMalagón T, i-Drolet M, i-Boily MC, i-Franco EL, i-Jit M, i-Brisson J, i-Brisson M. Ukukhusela okukhuselekileyo kwezigulane ze-papillomavirus ezimbini zomntu: ukuhlaziywa okucwangcisiweyo kunye nokuhlaziywa kwemeta. I-Lancet I-Dis Disfect. 2012 Oct; 12 (10): 781-9.
Nakalembe M, uBanura C, uNamujju PB, iMirembe FM. Amanqanaba okulwa ne-HPV16 / 18 kunye nama-anti-HPV31 / 33/35/45/52/58 amanqwelombazana phakathi kwe-ASV-4/4 ene-HPV16 / 18 enegciwane eligonywe nge-AS04 kunye nabangenagonywanga abantombazana base-Uganda abaneminyaka eyi-10-16. Umhlaza weAgent Cancer. 2014 Sep 1; 9: 29. i-doi: 10.1186 / 1750-9378-9-29.
Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS. Ukuthelekiswa kwe-immunogenicity ye-Cervarix® ne-Gardasil® yamagciwane e-papillomavirus yomntu we-oncogenic non-vaccine serotypes HPV-31, i-HPV-33, ne-HPV-45 kubantu abadala abane-HIV. Hum Vaccin Immunother. 2014 ngoMeyi; 10 (5): 1147-54. i-doi: 10.4161 / hv.27925.